2-(1,1-Dimethylethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyrazine | 914654-91-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(1,1-Dimethylethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyrazine
• 英文别名: 2-(tert-Butyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine；2-tert-butyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine
• CAS: 914654-91-4
• 化学式: C₉H₁₆N₄
• 分子量: 180.253
• InChiKey: KUASBBVZKOQOBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  42.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(1,1-dimethylethyl)-[1,2,4]triazolo[1,5-a]pyrazine 在 钯 氢气 、 乙醇 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以to give the title compound (0.47 g, 92%)的产率得到2-(1,1-Dimethylethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyrazine
  参考文献：
  名称：

  Quinoline derivatives as neurokinin receptor antagonists

  摘要：

  本发明涉及式（I）的取代喹啉腙，其中R1，R2，R3，R4，R5，X，Y和Z在此定义，包括它们的制药组合物及其在治疗由神经激肽-2和/或神经激肽-3（NK-3）受体介导的疾病中的应用。这些化合物可用于治疗和抑制这些疾病的方法中。

  公开号：

  US20090054440A1

文献信息

• HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
  申请人：Incyte Corporation

  公开号：US20180177784A1

  公开（公告）日：2018-06-28

  Disclosed are compounds of Formula (I′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

  本文披露了式（I′）的化合物，以及使用这些化合物作为免疫调节剂的方法，以及包含这些化合物的药物组合物。这些化合物抑制PD-1/PD-L1相互作用，并可用于治疗、预防或改善癌症或感染等疾病或疾病。
• [EN] NOVEL TRIAZOLE ANTIFUNGAL COMPOUNDS, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD, AND APPLICATION THEREOF<br/>[FR] NOUVEAUX COMPOSÉS ANTIFONGIQUES À BASE DE TRIAZOLES, COMPOSITION PHARMACEUTIQUE LES CONTENANT, PROCÉDÉ DE PRÉPARATION ET APPLICATION ASSOCIÉS
  申请人：SHANGHAI INST MATERIA MEDICA

  公开号：WO2014117318A1

  公开（公告）日：2014-08-07

  本发明提供了一类通式（I）表示的三氮唑类化合物、其光学异构体、或其药学上可接受的盐；以及所述化合物、其光学异构体或其药学上可接受的盐在制备抗真菌，特别是抗白假丝酵母菌、近平滑假丝酵母菌、光滑假丝酵母菌、新生隐球菌、石膏状小孢子菌、红色毛癣菌和/或烟曲霉菌的药物中的用途。本发明还提供了一种药物组合物，其包含治疗有效量的选自通式（I）表示的化合物、其光学异构体和其药学上可接受的盐中的一种或多种以及可药用辅料。
• AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Epizyme, Inc.

  公开号：US20200039998A1

  公开（公告）日：2020-02-06

  The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
• COMBINATION THERAPIES WITH EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200054635A1

  公开（公告）日：2020-02-20

  The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
• METHODS OF USING EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200113901A1

  公开（公告）日：2020-04-16

  The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.